Lithium aspartate is a chemical compound formed by the combination of lithium ions (Li⁺) with the anion of aspartic acid, a non‑essential α‑amino acid. In its simplest representation, the salt can be expressed as LiC₄H₆NO₄, indicating one lithium cation paired with a single aspartate anion. The compound belongs to the broader class of lithium salts of organic acids.
Chemical characteristics
- Molecular composition: Lithium (Li), carbon (C), hydrogen (H), nitrogen (N), and oxygen (O) in the ratio corresponding to the formula LiC₄H₆NO₄.
- Physical state: Typically supplied as a fine powder or crystalline solid for use in dietary supplements.
- Solubility: Expected to be water‑soluble due to the ionic nature of the lithium‑aspartate pairing, similar to other lithium salts.
Reported usage Lithium aspartate is occasionally marketed as a dietary supplement, often promoted for purported mood‑stabilizing or cognitive‑enhancing effects. Claims are generally derived from the broader context of lithium’s pharmacology, where lithium carbonate and lithium citrate are approved treatments for bipolar disorder. However, lithium aspartate itself has not been evaluated by major regulatory agencies (e.g., the U.S. Food and Drug Administration, European Medicines Agency) for safety, efficacy, or therapeutic indication.
Safety and regulatory status
- Regulatory classification: In most jurisdictions, lithium aspartate is sold as a “nutritional supplement” rather than as a pharmaceutical drug. Consequently, it is subject to dietary‑supplement regulations, which typically require less rigorous pre‑market testing than prescription medications.
- Toxicity considerations: Lithium, regardless of the accompanying anion, possesses a narrow therapeutic index. Excessive intake can lead to lithium toxicity, presenting symptoms such as tremor, gastrointestinal distress, renal impairment, and neurological effects. The specific toxicity profile of lithium aspartate has not been independently characterized in peer‑reviewed clinical studies.
Scientific literature A review of major scientific databases (e.g., PubMed, Scopus) yields few peer‑reviewed articles specifically addressing lithium aspartate. Most available information consists of product listings, anecdotal reports, or non‑scientific sources. Consequently, robust data on pharmacokinetics, pharmacodynamics, clinical efficacy, or long‑term safety are lacking.
Conclusion Lithium aspartate is a lithium salt of aspartic acid that appears primarily in the dietary‑supplement market. While chemically analogous to other lithium salts used medically, there is insufficient encyclopedic information regarding its pharmacological properties, clinical effectiveness, or safety profile. Users and clinicians should treat claims about its benefits with caution and consider the established safety concerns associated with lithium exposure.